Enclomiphene vs HCG
A side-by-side research comparison of Enclomiphene and HCG across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Enclomiphene | HCG |
|---|---|---|
| Full name | Enclomiphene Citrate | Human Chorionic Gonadotropin |
| Category | Hormone Replacement | Hormone Replacement |
| Status | Investigational drug | FDA Approved |
| Mechanism | Blocks estrogen receptors in the hypothalamus, reducing negative feedback and increasing GnRH pulsatility, which stimulates LH and FSH release for endogenous testosterone production. | Binds LH/CG receptors on Leydig cells, stimulating intratesticular testosterone synthesis and maintaining spermatogenesis via local paracrine signaling independent of pituitary FSH/LH. |
| Molecular weight | 598.09 Da | ~36,700 Da |
| Half-life | 10-14 hours | ~33 hours |
| Bioavailability | ~50% oral | ~100% (subcutaneous/intramuscular) |
| Typical dose | 12.5-25 mg | 500-1000 IU |
| Frequency | Daily | 2-3x per week |
| Route | Oral capsule | Subcutaneous injection |
Enclomiphene reported benefits
- Increased endogenous testosterone
- Preserved fertility
- Improved libido
- Enhanced energy and mood
- No testicular atrophy
HCG reported benefits
- Preserved testicular size
- Maintained fertility on TRT
- Intratesticular testosterone
- Improved mood (neurosteroid support)
- Pregnenolone/DHEA maintenance
Related comparisons
Research and educational reference only. Not medical advice.